Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jun 9;23(12):6445.
doi: 10.3390/ijms23126445.

Contribution of Cancer-Targeting Drugs toward Faster Clinical Application

Sungpil Yoon  1 , Hyung Sik Kim  1
Affiliations
Editorial

Contribution of Cancer-Targeting Drugs toward Faster Clinical Application

Sungpil Yoon et al. Int J Mol Sci. .

Abstract

With advances in cancer-targeting therapeutic strategies, cancer cells have developed drug resistance [...].

PubMed Disclaimer

Conflict of interest statement

The Authors declare no conflicts of interest regarding this study.

Figures

Figure 1
Figure 1
Scheme summarizing the initiation of faster clinical trials to apply novel therapeutic protocols for cancer-targeting drugs against resistant cancer. To initiate faster clinical trials, completing experimental tests and reviewing existing information can increase the possibility of initiating faster clinical applications for novel therapeutic protocols. Repeated and accumulated results will support the rapid clinical application of novel therapeutic protocols for cancer-targeting drugs against resistant cancer.
See this image and copyright information in PMC

References

    1. Oh Y., Lee J.S., Lee J.S., Park J.H., Kim H.S., Yoon S. JAK2 Inhibitor, Fedratinib, Inhibits P-gp Activity and Co-Treatment Induces Cytotoxicity in Antimitotic Drug-Treated P-gp Overexpressing Resistant KBV20C Cancer Cells. Int. J. Mol. Sci. 2022;23:4597. doi: 10.3390/ijms23094597. - DOI - PMC - PubMed
    1. Yoon S., Kim H.S. Drug Repositioning With an Anticancer Effect: Contributions to Reduced Cancer Incidence in Susceptible Individuals. Vivo. 2021;35:3039–3044. doi: 10.21873/invivo.12599. - DOI - PMC - PubMed
    1. Yoon S., Wang X., Vongpunsawad S., Tromp G., Kuivaniemi H. Editorial: FDA-Approved Drug Repositioning for P-Glycoprotein Overexpressing Resistant Cancer. Front. Oncol. 2021;11:632657. doi: 10.3389/fonc.2021.632657. - DOI - PMC - PubMed
    1. Caylioglu D., Meyer R.J., Hellmold D., Kubelt C., Synowitz M., Held-Feindt J. Effects of the Anti-Tumorigenic Agent AT101 on Human Glioblastoma Cells in the Microenvironmental Glioma Stem Cell Niche. Int. J. Mol. Sci. 2021;22:3606. doi: 10.3390/ijms22073606. - DOI - PMC - PubMed
    1. Mrkvova Z., Portesova M., Slaninova I. Loss of FADD and Caspases Affects the Response of T-Cell Leukemia Jurkat Cells to Anti-Cancer Drugs. Int. J. Mol. Sci. 2021;22:2702. doi: 10.3390/ijms22052702. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances